^
Association details:
Evidence:
Evidence Level:
Sensitive: D – Preclinical
Source:
Title:

The JAK1/2 Inhibitor Ruxolitinib Downregulates the Immune Checkpoint Protein B7-H3 in Multiple Myeloma

Published date:
11/06/2019
Excerpt:
The immune checkpoint protein B7-H3 is overexpressed in MMBM in PD compared to CR patients….Rux significantly reduced B7-H3 expression in MMBMMCs in patients with PD, MM cells (U266), and BM from patients in PD when co-cultured with stromal cells (HS-5) after 48-72 hours. Rux decreased B7H3 expression in the human MM xenograft model LAGλ-1A when cultured ex vivo. In addition, Rux suppressed B7-H3 at protein levels as shown with flow cytometric analysis and western blotting, consistent with the gene expression results.
DOI:
https://doi.org/10.1182/blood-2019-131047